| Backbone |
Third drug-based cART |
Overall |
| |
Efavirenz |
Nevirapina |
Lopinavir/r |
Atazanavir/r |
Fosamprenavir/r |
Saquinavir/r |
|
| TDF+FTC/3TC |
132 (56.9%) |
3 (1.3%) |
7 (3%) |
5 (2.1%) |
4 (1.7%) |
4 (1.7%) |
155 (66.8%) |
| ABC+3TC |
22 (9.5%) |
2 (0.8%) |
1 (0.4%) |
4 (1.7%) |
4 (1.7%) |
1 (0.4%) |
34 (14.7%) |
| AZT+3TC |
7 (3%) |
5 (2.1%) |
3 (1.3%) |
- |
1 (0.4%) |
- |
16 (6.8%) |
| ddI+3TC |
15 (6.5%) |
2 (0.8%) |
1 (0.4%) |
3 (1.3%) |
- |
1 (0.4%) |
22 (9.5%) |
| d4T+3TC |
3 (1.3%) |
- |
- |
- |
- |
- |
3 (1.3%) |
| Overall |
179 (77.2%) |
12 (5.2%) |
12 (5.2%) |
12 (5.2%) |
9 (3.8%) |
6 (2.5%) |
230 (99.1%)1 |
1. Two additional patients (0.9%) started a regimen based on AZT plus 3TC and ABC
ABC, abacavir; AZT, zidovudine; cART: combined antiretroviral treatment ; ddI. didanosine; d4T. Stavudine; FTC, Emtricitabine; IDU, intravenous drug user; 3TC,
lamivudine; R, ritonavir-boosted; TDF, tenofovir |
